The remission rate of venetoclax combined with azacitidine was higher than that of conventional chemotherapy in previously untreated adult acute myeloid leukemia. Venetoclax combined with azacitidine chemotherapy could reduce hematologic related side reactions and prolong the remission period and survival of AML patients.
Keyphrases
- acute myeloid leukemia
- allogeneic hematopoietic stem cell transplantation
- chronic lymphocytic leukemia
- end stage renal disease
- newly diagnosed
- ejection fraction
- disease activity
- prognostic factors
- peritoneal dialysis
- systemic lupus erythematosus
- rheumatoid arthritis
- clinical trial
- young adults
- childhood cancer
- acute lymphoblastic leukemia
- free survival
- patient reported
- replacement therapy